Ferroportin-inhibitor salt: patent evaluation WO2018192973

Area of Science:

• Biochemistry
• Pharmacology
• Medicine

Background:

• Iron is essential for bodily functions, but its irregular metabolism can lead to iron overload and associated metabolic disorders.
• Hepcidin and ferroportin interactions are key in iron regulation; their dysregulation causes conditions like hemochromatosis, beta-thalassemia, and sickle cell anemia.
• Current treatments for iron overload lack oral administration options targeting ferroportin inhibition.

Purpose of the Study:

• To introduce novel substituted benzoimidazole compounds as potential treatments for iron overload.
• To explore these compounds' mechanism of action as hepcidin mimetics inhibiting ferroportin.
• To present preclinical findings on these compounds in a mouse model.

Main Methods:

• Synthesis and characterization of novel substituted benzoimidazole compounds.
• Evaluation of compounds as hepcidin mimetics and ferroportin inhibitors.
• Preclinical studies in a mouse model of iron overload.

Main Results:

• The novel benzoimidazole compounds effectively inhibit ferroportin, preventing iron overload.
• These compounds demonstrated utility in preclinical models, showing promise for treating iron overload-related conditions.
• The compounds are identified as potential oral drug candidates for iron overload management.

Conclusions:

• The development of these novel benzoimidazole compounds represents a significant advancement in treating iron overload.
• These compounds are the first oral drug candidates to reach the preclinical stage for iron overload.
• Targeting ferroportin inhibition with these hepcidin mimetic compounds offers a promising therapeutic strategy.